Deuterated dtryptamine

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4 2026 1,2 HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (“FDA”) ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); HLP003 Phase 2 data demonstrated durable efficacy, with a mean ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score from baseline 12 months after two 16 mg doses administered three weeks apart, and 100% response and 71% remission rates based on a MADRS benchmark of ≤10, with remission rising to 100% using more recent peer-study benchmarks of ≤12 3 , 4 This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”) a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that it has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder (“MDD”). APPROACH enrolled adults with moderate to severe MDD, who experience inadequate response despite a stable antidepressant regimen. Completion of enrollment represents an important milestone for Helus Pharma and advances the Company toward the expected release of topline data in the fourth quarter of 2026. 1,2 Current first line antidepressant treatments are only effective in a small proportion of MDD patients. 5 For those that do not achieve remission, FDA-approved adjunctive atypical antipsychotics can provide modest benefit. 6 However, their use is often limited by side effects such as weight gain, cardiometabolic dysfunction, movement disorders (such as tardive dyskinesia) and sedation, often resulting in treatment discontinuation. 7 A novel adjunctive intermittent treatment such as HLP003 could potentially provide a more practical real-world solution. “Completion of enrollment in APPROACH ahead of schedule demonstrates the focus and execution of our clinical team, investigators and study partners. We thank them and the trial participants for achieving this important milestone. We believe the pace of enrollment of participants reflects not only the efficiency of our clinical team, but also the strength of our screening and site selection processes. Despite rigorous eligibility requirements, we successfully enrolled participants with baseline disease severity aligned with that of our Phase 2 study, reinforcing the quality and integrity of the Phase 3 study population,” said Eric So, Interim Chief Executive Officer of Helus Pharma. “With participant enrollment now complete, our focus turns to completing the study and preparing for topline data in Q4 2026. 1,2 We believe the durability, remission rates, and overall pro in our Phase 2 study support the potential of HLP003 to meaningfully improve outcomes for patients living with MDD, and we look forward to advancing the program through the next stage of development and toward a potential FDA New Drug Application in 2028.” 1,2 The milestone comes amid growing adoption of innovative, clinic-administered treatments for difficult-to-treat depression. Johnson & Johnson reported worldwide SPRAVATO® sales of US$584 million in the second quarter of 2026, an increase of approximately 25% from the first quarter of 2026 and 40.8% from the second quarter of 2025, including US$514 million in U.S. sales. 8 While HLP003 and SPRAVATO are distinct treatments with different mechanisms, clinical profiles and development pathways, Helus Pharma believes this continued growth provides further evidence of significant patient and provider demand for new approaches to treating depression and the increasing adoption of novel treatments in interventional psychiatry. The APPROACH study, and broader PARADIGM Program, incorporate key considerations outlined in the FDA’s recently finalized guidance. These include rigorous placebo-controlled evaluation, measures intended to support the interpretability of study results, assessment of clinical outcomes beyond the primary endpoint, defined safety monitoring and the collection of longer-term safety, durability and redosing data through the EXTEND study. “We have developed an industry leading development engine, which we believe will not only continue to drive the APPROACH study to completion, but will serve to accelerate EMBRACE and EXTEND studies, respectively,” 1,2 said Amir Inamdar, Chief Medical Officer. “The APPROACH study, and the PARADIGM Program in its entirety, are designed to generate robust evidence across efficacy, durability, safety and tolerability. The early completion of enrollment in APPROACH brings us closer to determining whether HLP003 can provide a durable clinical benefit within a practical adjunctive treatment model for people with MDD.” Enrollment is continuing in EMBRACE, the second pivotal study in the Phase 3 PARADIGM Program. Eligible participants from APPROACH and EMBRACE may also roll over into EXTEND, Helus Pharma’s long-term extension study, which is designed to further evaluate safety, durability of clinical effect and the potential role of redosing. Beyond its clinical development program, Helus Pharma has developed a broad intellectual property portfolio supporting its differentiated and proprietary NSA pipeline, with more than 350 patent applications filed and more than 100 patents granted worldwide. About the APPROACH Pivotal Study HLP003 is an investigational deuterated psilocin analogue that has received FDA Breakthrough Therapy Designation and APPROACH is the first pivotal trial to assess HLP003 as a potential adjunctive treatment for MDD. APPROACH has completed enrollment of 223 participants with moderate to severe MDD (MADRS ≥ 24) who are on a stable dose of antidepressant medication but are responding inadequately. Participants were randomized 1:1 to receive HLP003 (16 mg) or placebo. Each study arm evaluates a two-dose regimen, with doses administered three weeks apart. The primary endpoint is change from baseline in MADRS at six weeks after the first dose compared to placebo. The key secondary endpoint is change from baseline in MADRS at 12 weeks, compared to placebo. Participants are eligible to roll over into EXTEND, the blinded long-term extension study with opportunity for redosing. Topline data release to include both the primary and key secondary endpoints and is on track for Q4 2026. 1,2 About Helus Pharma Helus Pharma™, the commercial operating name of Cybin Inc. is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs - novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for GAD. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp. Notes There is no assurance that this timeline will be met or that the program will advance clinical trials, at all. Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development and recruitment of patients for participation in clinical trials are dependent on various factors and are based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, eligibility and exclusion criteria for the trial, design of the clinical trial, competition with other companies for clinical sites or patients, perceived risks and benefits of the prescription drug product candidate, the number, availability, location and accessibility of clinical trial sites, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company’s development efforts to date. There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See “Cautionary Notes and Forward-Looking Statements”. Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study TRANSFORM-2. Am J Psychiatry 2019; 176: 428-438. Definium Therapeutics, “Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder,” press release, June 22, 2026. Rush AJ, Trivedi MH, Wisniewski SR, et al. (2006). Acute and long-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D Report. AM J Psychiatry, 163, 1905-1917. McIntyre RS, Stahl SM, Shim SR, Pompili M, Goldberg JF, Correll CU, et al. Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. JAMA Psychiatry. Published online May 6, 2026. doi:10.1001/jamapsychiatry.2026.0658. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, et al. (2013) Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-analysis of Depression, Quality of Life, and Safety Outcomes. PLoSMed10(3):e1001403.doi:10.1371/journal.pmed.1001403 Johnson & Johnson, “Johnson & Johnson Reports Q2 2026 Results, Raises 2026 Outlook,” press release, July 15, 2026. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plan to readout topline data in the fourth quarter of 2026; the Company’s expectation that a novel adjunctive intermittent treatment such as HLP003 could provide a more practical real-world solution; the Company’s expectation that HLP003 is a transformative treatment option for patients living with MDD; the Company’s progress on and expectations with respect to the APPROACH trial; submission of FDA New Drug Application for HLP003 in 2028; the potential of HLP003 to meaningfully improve outcomes for patients living with MDD; the Company’s belief that the continued growth of the adoption of innovative, clinic-administered treatments for difficult-to-treat depression provides further evidence of significant patient and provider demand for new approaches to treating depression and the increasing adoption of novel treatments in interventional psychiatry; the Company’s belief that its drug development engine can continue to drive the APPROACH study to completion and serve to accelerate EMBRACE and EXTEND studies, respectively; the Company’s continued enrollment in EMBRACE; the possibility of eligible participants from APPROACH and EMBRACE to also roll over into EXTEND; and plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2026, and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company's pro SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The FDA, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations. Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. Investor Contact: Matthew Beck astr partners Managing Partner (917) 415-1750 Matthew.beck@astrpartners.com George Tziras Chief Business Officer Helus Pharma 1-866-292-4601 irteam@helus.com – or – media@helus.com Media Contact: Johnny Tokarczyk RXMD Public Relations Director jtokarczyk@rxmedyn.com (914) 772-7562

Issued on behalf of Helus Pharma™ Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarter USA News Group News Commentary NEW YORK, July 17, 2026 /PRNewswire/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in contingent value rights tied to development and regulatory milestones, taking total potential consideration to as much as $9.25 per share, or about $3.8 billion. The offer is a 26% premium to AtaiBeckley's prior close of $5.36, and the target jumped more than 30% before the bell. Across the sector, stocks that spent years priced as science projects moved sharply higher on one simple repricing event: a large-cap acquirer just validated the market. Key Takeaways A real price, not a rumor. Lilly is paying $6.75 per share in cash upfront, about $2.8 billion, plus up to $2.50 per share in milestone-linked CVRs. Both boards approved the deal, expected to close in Q3 subject to AtaiBeckley shareholder and regulatory approvals. The sector moved together. Compass Pathways rose about 7%, GH Research jumped roughly 15%, and Definium Therapeutics gained around 6%, a coordinated move suggesting the market read the deal as a statement about the category, not one company. Washington is no longer an obstacle. An April 2026 executive order directed the FDA to accelerate review of psychedelic candidates holding Breakthrough Therapy Designation. The agency published final clinical guidance on July 14, and HHS and the VA signed a cooperation agreement the day before. Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP) has a readout on the calendar. Its APPROACH study of HLP003, a deuterated psilocin analog holding FDA Breakthrough Therapy Designation for the adjunctive treatment of major depressive disorder, has surpassed 88% enrollment and is tracking to topline data in Q4 2026. A second asset with Phase 2 data in hand. HLP004, a deuterated DMT candidate for generalized anxiety disorder, showed roughly a 10-point improvement from baseline on the Hamilton Anxiety Rating Scale on top of standard of care at six weeks with composition of matter on the molecule. Helus closed a US$50 million offering on June 25 to fund both programs. The Deal That Changed the Conversation What Lilly bought is instructive. AtaiBeckley's lead asset, BPL-003, is an intranasal formulation of 5-MeO-DMT for treatment-resistant depression, and it holds FDA Breakthrough Therapy Designation. Phase 2b results linked it to statistically significant improvement beginning on Day 2, maintained through Day 57. The company is also advancing an MDMA-related program. Phase 3 topline data for BPL-003 is not expected until early 2029. Read that timeline again, because it is the whole story. Lilly committed up to $3.8 billion for an asset whose pivotal data is nearly three years out. That was not a purchase of proven revenue. It was a purchase of position, by a company that had already pledged more than $10 billion in upfront payments across eight acquisitions this year while building a neuroscience franchise alongside its obesity and diabetes business. Lilly has history here: Prozac reshaped the treatment of depression and powered its last great expansion before the GLP-1 era. Why Everything Else Moved Too Lilly is not alone in the neighborhood. Johnson & Johnson has been building in psychedelic-adjacent mental health for years, and analysts framed the deal as Lilly moving onto that ground. When a strategic acquirer sets a price, every comparable asset gets marked against it, and that is the mechanical reason the sector rallied. But the deal did not arrive into a vacuum, and the regulatory groundwork underneath it matters more than the headline. An April 2026 executive order directed the FDA to fast-track review of psychedelic therapies holding Breakthrough Therapy Designation, and the follow-through has been steady rather than symbolic. On July 13, HHS and the Department of Veterans Affairs signed a memorandum of understanding on cooperation in psychedelic drug trials, a meaningful signal given that the VA is the single largest potential customer for a PTSD or depression therapy in the country. On July 14, the FDA published final clinical guidance for developers and announced a public hearing, which Jefferies read as evidence the agency is trying to help sponsors rather than slow them. For a category that spent decades fighting the regulator, that is close to a reversal, and it explains why a large pharmaceutical company would underwrite a 2029 readout. The approval path is now legible enough to model. What Helus Pharma Is Actually Carrying Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company founded in 2019. It rebranded from Cybin Inc. and transferred its U.S. listing from the NYSE American to the Nasdaq Global Market in January 2026, a repositioning management framed as the shift from discovery-stage to commercial-ready. The company develops what it calls novel serotonergic agonists, or NSAs: synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. That matters commercially, because these are proprietary, patented chemical entities rather than naturally occurring compounds. Helus reports more than 350 patent filings with over 100 granted, and the U.S. composition of matter patent covering its lead candidates is expected to run to at least 2041. The lead program is HLP003, a deuterated psilocybin analog in Phase 3 for the adjunctive treatment of major depressive disorder, where it holds FDA Breakthrough Therapy Designation. The Phase 3 PARADIGM program comprises APPROACH, which has passed 88% enrollment and is tracking to a topline readout in Q4 2026; EMBRACE, a second pivotal study currently enrolling; and EXTEND, a rollover study collecting long-term safety and durability data. Helus has also partnered with TARA Mind on veteran access, which points to the program at the same VA channel Washington has been busy opening. The second asset, HLP004, is a deuterated DMT candidate for generalized anxiety disorder. The study randomized 36 patients 2-to-1 active to placebo at 20 mg or 2 mg, given as two intramuscular doses three weeks apart. Patients entered with an average baseline HAM-A of 22 and remained symptomatic despite ongoing standard-of-care antidepressant therapy. The 20 mg dose produced an average improvement of more than 10 points on the HAM-A by week six on top of that existing therapy. At six months, the pooled population showed 67% responders and 39% in remission, adverse events were transient, and no drug-related serious adverse events were recorded. Helus intends to complete the design of the next HLP004 study by the end of Q3 2026. Helus also has money in the bank against its readout. On June 25, 2026, it closed a US$50 million underwritten offering, selling 10,309,280 shares at US$4.85 through a syndicate led by Cantor and Barclays, with proceeds earmarked for HLP003, HLP004, the preclinical HLP005 program, and general corporate purposes. A clinical-stage company heading into a pivotal readout with fresh capital sits in a materially different position than one that has to raise into the result. The Rest of the Late-Stage Cohort The companies below are other publicly traded developers working the same therapeutic ground. They are named as sector context, not as endorsements or financial comparables to Helus Pharma, and several are developing competing therapies. Each sits at a different stage with a different molecule and a different risk profile. All of them moved on the Lilly news. Compass Pathways plc (NASDAQ: CMPS) is the closest analog to the Helus lead program. Its COMP360 psilocybin candidate met its primary endpoints in both the COMP005 and COMP006 Phase 3 studies in treatment-resistant depression, and it has reported six-month durability data. Evercore ISI upgraded the stock to Outperform with a $21 target, and Stifel raised its target to $21 on a Buy rating. Compass rose about 7% on the news, helped by a second-order connection: AtaiBeckley was historically its largest shareholder, though that stake had fallen to 4.96% as of a February 2026 filing. GH Research PLC (NASDAQ: GHRS) was the sharpest mover, jumping roughly 15%, and the reason is mechanistic. GH Research develops proprietary mebufotenin therapies, mebufotenin being 5-MeO-DMT, the same compound class underlying the BPL-003 asset Lilly just bought. Lead candidate GH001 is an inhalable formulation for treatment-resistant depression, with the intravenous GH002 behind it, and the company published its Phase 2b primary results in JAMA Psychiatry in March 2026. Shares traded near $29.75 against a 52-week range of $11.32 to $31.96, with a market capitalization around $2.04 billion. If the market wanted a direct read-across from the Lilly deal, GH Research was it. Definium Therapeutics, Inc. (NASDAQ: DFTX), formerly Mind Medicine, carries the deepest late-stage pipeline in the group. Lead candidate DT120 ODT, an orally disintegrating tablet of lysergide tartrate previously known as MM120, is in five Phase 3 studies spanning generalized anxiety disorder, major depressive disorder, and post-traumatic stress disorder, and holds FDA Breakthrough Therapy Designation in GAD. The company reported positive Phase 3 Emerge results in major depressive disorder, priced an upsized $700 million offering on the back of it, and has flagged a Phase 3 PTSD study called Haven for fiscal 2027. The stock gained about 6% on the deal. AtaiBeckley Inc. (NASDAQ: ATAI) is included because it is now the sector's benchmark, not despite it. Formed by the combination of atai Life Sciences and Beckley Psytech, its shares had gained roughly 31% year to date against a $1.97 billion market value as of Wednesday's close. As of this announcement, it no longer trades on its pipeline. It trades on a deal spread: the $6.75 cash consideration, CVRs worth up to $2.50 more, and the odds the transaction closes in Q3. That transition, from a science story to a takeout price, is exactly the event the rest of the sector is now measured against. Validation Is Not the Same Thing as Approval It is worth being clear-eyed about what today settled and what it did not. A large pharmaceutical company assigning a price to one pipeline does not make any other pipeline work. Helus Pharma has not reported its Phase 3 data, and HLP003 could miss. The HLP004 study enrolled 36 patients, which is a signal rather than proof, and its headline figure was a within-subject improvement from baseline, not a demonstration of superiority over placebo in a powered pivotal trial. The company generates no revenue and will need to fund a commercial launch it has not yet earned the right to run. What changed is narrower and still real: the exit is now visible. For most of this sector's history, the bear case was not simply that the science might fail but that even successful science had nowhere to go, because no large acquirer would touch a Schedule I derivative and no regulator would move. This morning, the first half of that stopped being an argument. Lilly wrote the check, the FDA published the guidance, the VA signed the memorandum. That leaves the sector's late-stage names with a cleaner question than they had a year ago: not whether anyone will ever want this, but whether the data reads out. For Helus Pharma, the answer arrives in the fourth quarter. CONTINUED... Follow Helus Pharma's progress toward its Q4 2026 APPROACH topline readout and get the full story and updates here . Track the Signals Before the Crowd The best positioning happens before the crowd catches on. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev. Article Source USA News Group [email protected] DISCLAIMER Nothing in this publication should be considered personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by USA News Group on behalf of Market Equities Limited ("Market Equities"), which wholly owns and operates USA News Group. Market Equities has been paid a fee by Creative Direct Marketing Group ("CDMG") for Helus Pharma advertising and digital media services. CDMG has been retained by Helus Pharma, pursuant to a services agreement, to provide various marketing and advertising services for an aggregate fee. This article was prepared and published pursuant to that services agreement. Market Equities and its owners, operators, directors, and affiliates do not currently own any shares of Cybin Inc., doing business as Helus Pharma, but reserve the right to buy, sell, or hold shares of Helus Pharma at any time without further notice, commencing immediately and on an ongoing basis, in the open market, through private placements, and/or through other investment vehicles. There may also be third parties who hold shares of Helus Pharma and may liquidate their shares, which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because a conflict of interest exists due to the compensation described above, individuals are strongly encouraged to not use this publication as the basis for any investment decision. We also expect to receive further compensation as part of an ongoing digital media effort to increase visibility for the company, and no further notice will be given, but let this disclaimer serve as notice that all material disseminated by Market Equities has been reviewed and approved for distribution on behalf of Helus Pharma by CDMG; this is a paid advertisement. Cautionary Note Regarding Clinical Results. Clinical results referenced in this article, including Phase 2 signal detection data for HLP004 and enrollment status and timing for the HLP003 Phase 3 PARADIGM program, are as reported by Helus Pharma. The HLP004 Phase 2 signal detection study enrolled 36 patients and was not designed or powered as a pivotal trial; the reported Hamilton Anxiety Rating Scale improvement is a within-subject change from baseline on top of standard of care and is not a demonstration of statistical superiority over placebo. Breakthrough Therapy Designation does not constitute approval, does not guarantee approval, and does not indicate that a candidate is safe or effective. Early or interim clinical results do not guarantee the outcome of later-stage trials, regulatory approval, or commercialization. Helus Pharma does not generate revenue and expects to require additional capital. Cautionary Note Regarding the AtaiBeckley Transaction. This article references a proposed acquisition of AtaiBeckley Inc. (Nasdaq: ATAI) by Eli Lilly and Company (NYSE: LLY), which the parties have announced is expected to close in the third quarter of 2026 subject to AtaiBeckley stockholder approval and customary regulatory approvals. Helus Pharma is not a party to that transaction. Nothing in this article states, suggests, or should be interpreted to suggest that Helus Pharma is, has been, or will be the subject of any acquisition, merger, business combination, partnership, or similar transaction, that any such transaction has been proposed or is under discussion, or that any third party has expressed any interest in Helus Pharma. The AtaiBeckley transaction has no bearing on the valuation, prospects, clinical outcomes, or regulatory path of Helus Pharma. Investors should review the parties' filings with the U.S. Securities and Exchange Commission at for complete information regarding that transaction and its associated risks. Forward-Looking Statements. This publication may contain forward-looking statements within the meaning of applicable securities laws, including statements regarding expected clinical milestones, trial readouts and their timing, regulatory pathways, commercialization timelines, business plans, and future performance. Forward-looking statements can often be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "may," "will," "should," "could," or the negative of such terms, or other comparable terminology. These statements are based on current expectations, estimates, and projections and involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to, risks related to the development and commercialization of novel serotonergic agonist therapies, the ability to achieve clinical and regulatory milestones, the risk that clinical trials fail to meet their endpoints, regulatory approvals, the scheduling status of controlled substances, market acceptance, competition, the need for additional capital that may not be available on favorable terms, and general economic conditions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this publication. Neither the company nor any other party undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers should conduct their own due diligence before making any investment decisions. This disclaimer, together with your access to and use of this content, shall be governed by and construed in accordance with the laws of Ireland. Third-party companies referenced (LLY, ATAI, CMPS, GHRS, DFTX) are provided solely as market and sector context and are not peers, partners, or financial comparables of Cybin Inc. doing business as Helus Pharma. Several are engaged in the development of competing therapies. All third-party performance figures, share prices, and market capitalizations are approximate, are as of the dates indicated, and are subject to change. Analyst ratings and price targets referenced are the opinions of the issuing firms only, are not a recommendation by us, and should not be relied upon. SOURCE USA News Group 21% more press release views with Request a Demo